论文标题：Small-molecule anti-COVID-19 drugs and a focus on China’s homegrown mindeudesivir (VV116)

期刊： Frontiers of Medicine

作者：Qiuyu Cao, Yi Ding, Yu Xu, Mian Li, Ruizhi Zheng, Zhujun Cao, Weiqing Wang, Yufang Bi, Guang Ning, Yiping Xu, Ren Zhao

发表时间：15 Dec 2023

DOI：10.1007/s11684-023-1037-3

微信链接：点击此处阅读微信文章

导 读

上海交通大学医学院附属瑞金医院赵仁等在Frontiers of Medicine发表了题为《小分子抗新型冠状病毒药物及中国自主研发的民得维（VV116）研究进展》（Small-molecule anti-COVID-19 drugs and a focus on China’s homegrown mindeudesivir (VV116)）的综述文章。本文系统总结了全球小分子抗新冠病毒病药物研发进展，重点分析了中国自主研发的四种口服抗COVID-19药物（阿兹夫定、先诺特韦-利托那韦、莱瑞特韦及民德维/VV116）的药理机制与临床证据，并深入探讨了VV116在临床前研究、药代动力学特性及III期临床试验中的治疗潜力。

The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous efforts to develop therapeutic agents that target severe acute respiratory syndrome coronavirus 2 to control viral infection. So far, a few small-molecule antiviral drugs, including nirmatrelvir–ritonavir (Paxlovid), remdesivir, and molnupiravir have been marketed for the treatment of COVID-19. Nirmatrelvir–ritonavir has been recommended by the World Health Organization as an early treatment for outpatients with mild-to-moderate COVID-19. However, the existing treatment options have limitations, and effective treatment strategies that are cost-effective and convenient for tackling COVID-19 are still needed. To date, four domestically developed oral anti-COVID-19 drugs have been granted conditional market approval in China. These drugs include azvudine, simnotrelvir–ritonavir (Xiannuoxin), leritrelvir, and mindeudesivir (VV116). Preclinical and clinical studies have explored the efficacy and tolerability of mindeudesivir and supported its early use in mild-to-moderate COVID-19 cases at high risk for progression. In this review, we discuss the most recent findings regarding the pharmacological mechanism and therapeutic effects focusing on mindeudesivir and other small-molecule antiviral agents for COVID-19. These findings will expand our understanding and highlight the potential widespread application of China’s homegrown anti-COVID-19 drugs.

新冠病毒病（COVID-19）大流行推动了针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2，简称新冠病毒）的抗病毒药物研发，以控制病毒感染。截至目前，已有多款小分子抗病毒药物获批用于COVID-19的治疗，包括奈玛特韦–利托那韦（Paxlovid）、瑞德西韦（remdesivir）和莫诺拉韦（molnupiravir）。其中，奈玛特韦–利托那韦被世界卫生组织（WHO）推荐作为轻至中度COVID-19门诊患者的早期治疗用药。然而，现有的治疗手段存在局限性，仍然需要开发更具成本效益且便捷的有效治疗策略。目前，中国已有四款自主研发的口服抗COVID-19药物获得有条件上市批准。这些药物包括阿兹夫定（azvudine）、先诺特韦–利托那韦（先诺欣，simnotrelvir–ritonavir）、来瑞特韦（leritrelvir）及民得维（mindeudesivir，VV116）。临床前及临床研究已证实民得维的疗效与耐受性，支持其用于具有疾病进展风险的轻至中度COVID-19患者的早期干预。本综述重点探讨了民得维及其他小分子抗COVID-19药物的药理机制与治疗进展。这些发现将拓宽我们的认知，并凸显中国自主研发的抗 COVID-19 药物潜在的广泛应用前景。

期刊介绍

Frontiers of Medicine专注于发表临床医学和基础医学领域的最新研究成果，旨在通过全球医疗专业人员之间的交流促进健康和医疗保健的发展。该刊采用严格的同行评审和编辑流程，确保发表的文章的科学准确性、新颖性和重要性。

原文信息

标题

Small-molecule anti-COVID-19 drugs and a focus on China’s homegrown mindeudesivir (VV116)

作者

Qiuyu Cao^1,2, Yi Ding^1,2, Yu Xu^1,2, Mian Li^1,2, Ruizhi Zheng^1,2, Zhujun Cao³, Weiqing Wang^1,2, Yufang Bi^1,2, Guang Ning^1,2, Yiping Xu⁴, Ren Zhao⁵

机构

1. Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

2. Shanghai National Clinical Research Center for Metabolic Diseases, State Key Laboratory of Medical Genomics, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

3. Department of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

4. Clinical Trials Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

5. Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

通讯作者

Yiping Xu, Ren Zhao

引用这篇文章

Qiuyu Cao, Yi Ding, Yu Xu, Mian Li, Ruizhi Zheng, Zhujun Cao, Weiqing Wang, Yufang Bi, Guang Ning, Yiping Xu, Ren Zhao. Small-molecule anti-COVID-19 drugs and a focus on China’s homegrown mindeudesivir (VV116). Front. Med., 2023, 17(6): 1068–1079 https://doi.org/10.1007/s11684-023-1037-3

https://journal.hep.com.cn/fmd/EN/10.1007/s11684-023-1037-3

https://link.springer.com/article/10.1007/s11684-023-1037-3

感谢作者对Frontiers of Medicine的信任和支持。

《前沿》系列英文学术期刊

由教育部主管、高等教育出版社主办的《前沿》（Frontiers）系列英文学术期刊，于2006年正式创刊，以网络版和印刷版向全球发行。系列期刊包括基础科学、生命科学、工程技术和人文社会科学四个主题，是我国覆盖学科最广泛的英文学术期刊群，其中12种被SCI收录，其他也被A&HCI、Ei、MEDLINE或相应学科国际权威检索系统收录，具有一定的国际学术影响力。系列期刊采用在线优先出版方式，保证文章以最快速度发表。

中国学术前沿期刊网

http://journal.hep.com.cn